My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Sonoma Pharmaceuticals (SNOA)
NASDAQ:SNOA
SNOA nasdaq
United States
Sonoma Pharmaceuticals

Sonoma Pharmaceuticals Stock Analysis & Ratings

Sonoma Pharmaceuticals Stock Analysis Overview

Smart Score
N/A
Not Ranked
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.

Stock Chart

SNOA

SNOA Stock Stats

Previous Close$4.68
Open$4.64
Bid0 x 0
Ask0 x 0
Today’s Range$4.3 - $4.705
52-Week Range$4.30 - $15.19
Volume124.50K
Average Volume2.42M
Market Cap$13.38M
Beta0.77
P/E Ratio-1.7
EPS-2.70
Earnings DateFeb 10, 2022

Company Description

Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. The company offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Petaluma, CA.
Sector
Healthcare
Industry
Drug Manufacturers
CEO
Amy Trombly
Employees
200
ISIN
US83558L2043
Address
645 Molly Lane, Woodstock, GA, 30189, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

SNOA FAQ

What was Sonoma Pharmaceuticals’s price range in the past 12 months?
Sonoma Pharmaceuticals lowest stock price was $4.30 and its highest was $15.19 in the past 12 months.
    What is Sonoma Pharmaceuticals’s market cap?
    Sonoma Pharmaceuticals’s market cap is $13.38M.
      What is Sonoma Pharmaceuticals’s price target?
      Currently, no data Available
      What do analysts say about Sonoma Pharmaceuticals?
      Not enough analysts have published a price target to provide an average price target.
      When is Sonoma Pharmaceuticals’s upcoming earnings report date?
      Sonoma Pharmaceuticals’s upcoming earnings report date is Feb 10, 2022 which is in 68 days.
        How were Sonoma Pharmaceuticals’s earnings last quarter?
        Sonoma Pharmaceuticals released its earnings results on Nov 15, 2021. The company reported -$0.043 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.043.
          Is Sonoma Pharmaceuticals overvalued?
          According to Wall Street analysts Sonoma Pharmaceuticals’s price is currently Overvalued.
            Does Sonoma Pharmaceuticals pay dividends?
            Sonoma Pharmaceuticals does not currently pay dividends.
            What is Sonoma Pharmaceuticals’s EPS estimate?
            Sonoma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Sonoma Pharmaceuticals have?
            Sonoma Pharmaceuticals has 3,100,000 shares outstanding.
              What happened to Sonoma Pharmaceuticals’s price movement after its last earnings report?
              Sonoma Pharmaceuticals reported an EPS of -$0.043 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.017%.
                Which hedge fund is a major shareholder of Sonoma Pharmaceuticals?
                Among the largest hedge funds holding Sonoma Pharmaceuticals’s share is Hussman Strategic Advisors Inc. It holds Sonoma Pharmaceuticals’s shares valued at N/A.

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis